Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate
NCT ID: NCT00880672
Last Updated: 2013-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2008-01-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels
NCT00062790
Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue
NCT01473030
Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)
NCT00274417
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00375765
Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker
NCT00680680
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dutasteride
oral, 5mg, once per day, 2 weeks
dutasteride
5mg, oral, daily, 2-4 weeks
placebo
oral, 5mg, once per day, 2 weeks
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dutasteride
5mg, oral, daily, 2-4 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 50 years old or older
* International Prostate Symptom Score (IPSS) \>8
* Maximum flow rate (Qmax) \<15 ml/s
* transurethral resection of the prostate (TURP)
Exclusion Criteria
* urinary tract infection (UTI)
* liver disease
* renal disease
* unexplained hematuria
* prostate specific antigen (PSA) \> 4ng/ml (included if prostate biopsy was negative)
* interstitial cystitis
* bladder cancer or prostate cancer
* pelvic surgery or irradiation
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Korean Urological Association
OTHER
GlaxoSmithKline
INDUSTRY
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ja Hyeon Ku,
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jae-Seung paick, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Dept. of Urology, Seoul National University Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JHKu1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.